- Report
- January 2026
- 196 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- June 2026
- 191 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- October 2025
- 160 Pages
Global
From €3597EUR$3,950USD£3,102GBP
- Report
- October 2025
- 160 Pages
Global
From €3597EUR$3,950USD£3,102GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,117USD£3,124GBP
- Report
- August 2025
- 180 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- June 2026
- 291 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- July 2025
- 155 Pages
Global
From €4234EUR$4,650USD£3,652GBP
- Report
- June 2026
- 198 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- June 2026
- 199 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- June 2026
- 197 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- January 2026
- 194 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- January 2026
- 182 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- January 2026
- 191 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- January 2026
- 199 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- January 2026
- 198 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- January 2026
- 199 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- January 2026
- 193 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more